Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine, Gemcitabine, and Docetaxel in Recurrent Osteosarcoma
NCT03598595Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2019
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hydroxychloroquine in osteosarcoma (OS), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2019; status: active, not recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT03598595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03598595.